HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab.

AuthorsSilvia Peter, Norbert Hausmann, Antonius Schuster, Hubert Friedrich Boehm
JournalClinical & experimental ophthalmology (Clin Exp Ophthalmol) 2008 Jan-Feb Vol. 36 Issue 1 Pg. 94-6 ISSN: 1442-9071 [Electronic] Australia
PMID18290962 (Publication Type: Case Reports, Letter)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
Topics
  • Aged
  • Angiogenesis Inhibitors (administration & dosage, adverse effects, therapeutic use)
  • Antibodies, Monoclonal (administration & dosage, adverse effects, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Colonic Neoplasms (drug therapy, secondary)
  • Female
  • Humans
  • Injections, Intravenous
  • Magnetic Resonance Imaging
  • Posterior Leukoencephalopathy Syndrome (chemically induced, diagnosis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: